

# Risk Characterisation

## In this guide

### [In this guide](#)

1. [Background and Introduction - \*Garcinia cambogia\*](#)
2. [Chemical composition - \*Garcinia cambogia\*](#)
3. [Data from authoritative bodies - \*Garcinia cambogia\*](#)
4. [Chemical composition of the plant - \*Garcinia cambogia\*](#)
5. [Regulatory status in different fields of use and geographic regions - \*Garcinia cambogia\*](#)
6. [Adverse effects linked to the consumption of \*G. cambogia\* Desr. - \*Garcinia cambogia\*](#)
7. [Data published in the literature - \*Garcinia cambogia\*](#)
8. [Clinical trials - \*Garcinia cambogia\*](#)
9. [Drug interactions - \*Garcinia cambogia\*](#)
10. [Conclusions of the Plants WG and the Human Nutrition Expert Committee - \*Garcinia cambogia\*](#)
11. [Conclusions of ANSES - \*Garcinia cambogia\*](#)
12. [AESAN - \*Garcinia cambogia\*](#)
13. [Australian TGA - \*Garcinia cambogia\*](#)
14. [BfR \(German Federal Institute for Risk Assessment\) - \*Garcinia cambogia\*](#)
15. [EFSA - \*Garcinia cambogia\*](#)
16. [Health Canada - \*Garcinia cambogia\*](#)
17. [NCCIH - \*Garcinia cambogia\*](#)
18. [Data from literature search - \*Garcinia cambogia\*](#)
19. [Exposure - \*Garcinia cambogia\*](#)
20. [Risk Characterisation - \*Garcinia cambogia\*](#)
21. [Questions to the Committee - \*Garcinia cambogia\*](#)
22. [Abbreviations - \*Garcinia cambogia\*](#)
23. [References - \*Garcinia cambogia\*](#)

**This is a discussion paper. It does not reflect the views of the Committee. It should not be cited.**

195. The presence of HCA in food supplements is considered medicinal according to the UK MHRA (see paragraph 8). From the Brief market analysis described in the Exposure section, it is clear that some products are medicinal.

196. Data from nutrивigilance programs/schemes of authoritative bodies and literature have reported the following adverse effects following consumption of supplements containing *G. cambogia*: hepatic, digestive (pancreatitis), cardiac and muscular (rhabdomyolysis) damage, psychiatric, metabolic disorders, as well as drug-drug interactions. However, the mode of action of *G. cambogia* and its extracts have yet to be fully elucidated.